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For prevention and management of diabetes complications in children and adolescents, please refer to Section 12 "Children and Adolescents."
Atherosclerotic cardiovascular disease (ASCVD)ddefined as acute coronary syndromes (ACSs), a history of myocardial infarction (MI), stable or unstable angina, coronary or other arterial revascularization, stroke, transient ischemic attack, or peripheral arterial disease presumed to be of atherosclerotic origindis the leading cause of morbidity and mortality for individuals with diabetes and is the largest contributor to the direct and indirect costs of diabetes. The common conditions coexisting with type 2 diabetes (e.g., hypertension and dyslipidemia) are clear risk factors for ASCVD, and diabetes itself confers independent risk. Numerous studies have shown the efficacy of controlling individual cardiovascular risk factors in preventing or slowing ASCVD in people with diabetes. Large benefits are seen when multiple risk factors are addressed simultaneously. There is evidence that measures of 10-year coronary heart disease (CHD) risk among U.S. adults with diabetes have improved significantly over the past decade (1) and that ASCVD morbidity and mortality have decreased (2) (3) (4) .
In all patients with diabetes, cardiovascular risk factors should be systematically assessed at least annually. These risk factors include hypertension, dyslipidemia, smoking, a family history of premature coronary disease, and the presence of albuminuria. Abnormal risk factors should be treated as described in these guidelines.
HYPERTENSION/BLOOD PRESSURE CONTROL

Recommendations
Screening and Diagnosis
c Blood pressure should be measured at every routine visit. Patients found to have elevated blood pressure should have blood pressure confirmed on a separate day. B Goals c Most patients with diabetes and hypertension should be treated to a systolic blood pressure goal of ,140 mmHg and a diastolic blood pressure goal of ,90 mmHg. A c Lower systolic and diastolic blood pressure targets, such as 130/80 mmHg, may be appropriate for individuals at high risk of cardiovascular disease, if they can be achieved without undue treatment burden. C c In pregnant patients with diabetes and chronic hypertension, blood pressure targets of 120-160/80-105 mmHg are suggested in the interest of optimizing long-term maternal health and minimizing impaired fetal growth. E Treatment c Patients with confirmed office-based blood pressure .140/90 mmHg should, in addition to lifestyle therapy, have prompt initiation and timely titration of pharmacologic therapy to achieve blood pressure goals. A c Patients with confirmed office-based blood pressure .160/100 mmHg should, in addition to lifestyle therapy, have prompt initiation and timely titration of two drugs or a single pill combination of drugs demonstrated to reduce cardiovascular events in patients with diabetes. A c Treatment for hypertension should include drug classes demonstrated to reduce cardiovascular events in patients with diabetes (ACE inhibitors, angiotensin receptor blockers, thiazide-like diuretics, or dihydropyridine calcium channel blockers). Multipledrug therapy is generally required to achieve blood pressure targets (but not a combination of ACE inhibitors and angiotensin receptor blockers). A c An ACE inhibitor or angiotensin receptor blocker, at the maximum tolerated dose indicated for blood pressure treatment, is the recommended first-line treatment for hypertension in patients with diabetes and urinary albumin-tocreatinine ratio $300 mg/g creatinine (A) or 30-299 mg/g creatinine (B). If one class is not tolerated, the other should be substituted. B c For patients treated with an ACE inhibitor, angiotensin receptor blocker, or diuretic, serum creatinine/ estimated glomerular filtration rate and serum potassium levels should be monitored. B c For patients with blood pressure .120/80 mmHg, lifestyle intervention consists of weight loss if overweight or obese; a Dietary Approaches to Stop Hypertensionstyle dietary pattern including reducing sodium and increasing potassium intake; moderation of alcohol intake; and increased physical activity. B
Hypertension, defined as a sustained blood pressure $140/90 mmHg, is a common comorbidity of type 1 and type 2 diabetes. The prevalence of hypertension depends on type of diabetes, age, sex, BMI, and race/ethnicity. Hypertension is a major risk factor for both ASCVD and microvascular complications. In type 1 diabetes, hypertension is often the result of underlying diabetic kidney disease, while in type 2 diabetes, it usually coexists with other cardiometabolic risk factors. Please refer to the American Diabetes Association (ADA) position statement "Diabetes and Hypertension" for a detailed review (5).
Blood pressure should be measured by a trained individual and should follow the guidelines established for the general population: measurement in the seated position, with feet on the floor and arm supported at heart level, after 5 min of rest. Cuff size should be appropriate for the upper-arm circumference. Elevated values should be confirmed on a separate day. Postural changes in blood pressure and pulse may be evidence of autonomic neuropathy and therefore require adjustment of blood pressure targets. Home blood pressure self-monitoring and 24-h ambulatory blood pressure monitoring may provide evidence of white-coat hypertension, masked hypertension, or other discrepancies between office and "true" blood pressure. Studies in individuals without diabetes found that home measurements may better correlate with ASCVD risk than office measurements (6, 7) . However, most of the evidence of benefits of hypertension treatment in people with diabetes is based on office measurements.
Treatment Goals
Epidemiological analyses show that blood pressure .115/75 mmHg is associated with increased cardiovascular event rates and mortality in individuals with diabetes (8) . Randomized clinical trials have demonstrated the benefit (reduction of CHD events, stroke, and diabetic kidney disease) of lowering blood pressure to ,140 mmHg systolic and ,90 mmHg diastolic in individuals with diabetes (9, 10) . There is limited prespecified clinical trial evidence for the benefits of lower systolic blood pressure (SBP) or diastolic blood pressure (DBP) targets (11) . A meta-analysis of randomized trials of adults with type 2 diabetes comparing intensive blood pressure targets (upper limit of 130 mmHg systolic and 80 mmHg diastolic) with standard targets (upper limit of 140-160 mmHg systolic and 85-100 mmHg diastolic) found no significant reduction in mortality or nonfatal MI. There was a statistically significant 35% relative risk (RR) reduction in stroke with intensive targets, but the absolute risk reduction was only 1%, and intensive targets were associated with an increased risk for adverse events such as hypotension and syncope (12 ACCORD. The ACCORD trial examined whether an SBP of ,120 mmHg in patients with type 2 diabetes at high risk for ASCVD provided greater cardiovascular protection than an SBP of 130-140 mmHg (13) . The study did not find a benefit in the primary end point (nonfatal MI, nonfatal stroke, and cardiovascular death) comparing intensive blood pressure treatment (intensive BP; goal ,120 mmHg, average blood pressure achieved 119/64 mmHg on 3.4 medications) with standard treatment (standard BP; average blood pressure achieved 143/70 mmHg on 2.1 medications). However, a follow-up analysis found a strong interaction between glycemic control and blood pressure control. Compared with the standard glycemia/standard BP control group in the blood pressure trial, the intensive BP/intensive glycemia, intensive BP/standard glycemia, and standard BP/intensive glycemia groups all showed benefit for reducing the risk of major cardiovascular disease (14) . Stroke was significantly reduced in the intensive BP treatment groups, but the intensive BP/ intensive glycemia group showed no evidence of incremental benefit compared with either single intensive intervention (14) . Thus, more intensive blood pressure control may be reasonable in certain motivated, ACCORD-like patients (40-79 years of age with prior evidence of cardiovascular disease or multiple cardiovascular risk factors) who have been educated about the added treatment burden, side effects, and costs of more intensive blood pressure control and for patients who prefer to lower their risk of stroke beyond what can be achieved through standard care.
ADVANCE. In ADVANCE, the active blood pressure intervention arm (a single-pill, fixed-dose combination of perindopril and indapamide) showed a significant reduction in the risk of the primary composite end point (major macrovascular or microvascular event) and significant reductions in the risk of death from any cause and of death from cardiovascular causes (15) . The baseline blood pressure among the study subjects was 145/81 mmHg. Compared with the placebo group, the patients treated with a single-pill, fixed-dose combination of perindopril and indapamide experienced an average reduction of 5.6 mmHg in SBP and 2.2 mmHg in DBP. The final blood pressure in the treated group was 136/73 mmHg, not quite the intensive or tight control achieved in ACCORD. The recently published 6-year follow-up of the ADVANCE trial, the ADVANCE-PostTrial Observational Study (ADVANCE-ON), reported that the reductions in the risk of death from any cause and of death from cardiovascular causes in the intervention group were attenuated but remained significant (16) .
HOT. The Hypertension Optimal Treatment (HOT) trial included patients with and without diabetes and compared DBP targets of #90, #85, and #80 mmHg. Post hoc analyses found cardiovascular benefit with more intensive targets in the subpopulation with diabetes (17) . The HOT trial results, taken together with the higher quality data from ACCORD and ADVANCE, support the current recommendation to achieve blood pressure levels ,140/90 mmHg, with lower targets in selected patients.
SPRINT. The Systolic Blood Pressure Intervention Trial (SPRINT) was a multicenter, randomized controlled trial that compared two strategies for treating SBP with either the standard target of ,140 mmHg or an intensive target of ,120 mmHg; primary outcomes were MI, ACS, stroke, heart failure, and death due to cardiovascular disease. Patients assigned to the intensive SBP target of ,120 mmHg, compared with a target SBP of 140 mmHg, had reduced RR of cardiovascular events by almost a third and of death by almost a quarter, though risks of electrolyte abnormalities and acute kidney injury were increased (18) . Of note, patients with diabetes were excluded from participating in this trial, so the results have no direct implications for blood pressure management in patients with diabetes.
Systolic Blood Pressure
The evidence that SBP .140 mmHg is harmful is irrefutable, suggesting that clinicians promptly initiate and titrate therapy to achieve and maintain SBP ,140 mmHg in most patients. For some patients, lower SBP targets closer to 130 mmHg are appropriate. A recent systematic review and meta-analysis evaluating SBP lowering in adults with type 2 diabetes showed that each 10 mmHg reduction of SBP was associated with significantly lower risk of mortality, cardiovascular events, CHD, stroke, albuminuria, and retinopathy. However, when trials were stratified by mean baseline SBP $140 mmHg or ,140 mmHg, blood pressure-lowering treatment was associated with lower risks of stroke and albuminuria, regardless of initial SBP (9) . Therefore, individuals in whom cardiovascular disease risk, particularly stroke, is a concern may, as part of shared decision making, have lower systolic targets than 140 mmHg. This is especially true if lower blood pressure can be achieved with few drugs and without side effects of therapy. For older adults, treating to an SBP of ,130 mmHg has not been shown to improve cardiovascular outcomes (19) .
Diastolic Blood Pressure
Similarly, strong evidence from randomized clinical trials supports DBP targets of ,90 mmHg. These targets are in harmony with the Eighth Joint National Committee (JNC 8) recommendation of a DBP threshold of ,90 mmHg for individuals over 18 years of age with diabetes (11) . A DBP of ,80 mmHg may still be appropriate for patients with long life expectancy, chronic kidney disease, elevated urinary albumin excretion, evidence of cardiovascular disease, or additional risk factors such as dyslipidemia, smoking, or obesity (17) . In older adults, treating to a DBP of ,70 mmHg has been associated with a greater risk of mortality (20) .
Treatment Strategies
Lifestyle Intervention
Although there are no well-controlled studies of diet and exercise in the treatment of elevated blood pressure or hypertension in individuals with diabetes, the Dietary Approaches to Stop Hypertension (DASH) study evaluated the impact of healthy dietary patterns in individuals without diabetes and has shown antihypertensive effects similar to those of pharmacologic monotherapy.
Lifestyle therapy consists of reducing excess body weight through caloric restriction, restricting sodium intake (,2,300 mg/day), increasing consumption of fruits and vegetables (8-10 servings per day) and low-fat dairy products (2-3 servings per day), avoiding excessive alcohol consumption (no more than 2 servings per day in men and no more than 1 serving per day in women) (21) , and increasing activity levels (11) .
These lifestyle (nonpharmacologic) strategies may also positively affect glycemia and lipid control and should be encouraged in those with even mildly elevated blood pressure, although the impact of lifestyle therapy on cardiovascular events has not been established. Nonpharmacologic therapy is reasonable in individuals with diabetes and mildly elevated blood pressure (SBP .120 mmHg or DBP .80 mmHg). If the blood pressure is confirmed to be $140 mmHg systolic and/or $90 mmHg diastolic, pharmacologic therapy should be initiated along with nonpharmacologic therapy (11) . A lifestyle therapy plan should be developed in collaboration with the patient and discussed as part of diabetes management.
Pharmacologic Interventions
Lowering of blood pressure with regimens based on a variety of antihypertensive agents, including ACE inhibitors, angiotensin receptor blockers (ARBs), diuretics, and calcium channel blockers has been shown to be effective in reducing cardiovascular events (9, 22) .
In people with diabetes and albuminuria, ACE inhibitors or ARBs may have unique advantages for initial or early treatment of hypertension. In a trial of individuals at high risk for ASCVD, including a large subset with diabetes, an ACE inhibitor reduced ASCVD outcomes and the development of albuminuria when compared with placebo, even after adjustment for differences in blood pressure, an effect that has been termed a "blood pressure independent effect" (23). In patients with congestive heart failure, including subgroups with diabetes, ARBs have been shown to reduce major ASCVD outcomes (24-26). Among patients with type 2 diabetes, urine albumin-to-creatinine ratio (UACR) $300 mg/g creatinine, and elevated serum creatinine concentration, an ARB significantly reduced progression of kidney disease compared with placebo (27) . A meta-analysis confirmed that treatment of patients with diabetic kidney disease with an ACE inhibitor or ARB reduces the risk of progressing to end-stage renal disease, though strong evidence of benefit was limited to participants with baseline UACR $300 mg/g creatinine (28) . Smaller trials also suggest reduction in composite cardiovascular events and reduced progression of advanced nephropathy (29) (30) (31) .
However, the superiority of ACE inhibitors or ARBs over other antihypertensive agents for prevention of cardiovascular outcomes has not been consistently shown for all patients with diabetes (22, 28, 32, 33) . In particular, a recent meta-analysis suggests that thiazidetype diuretics or dihydropyridine calcium channel blockers have cardiovascular benefit similar to that of ACE inhibitors or ARBs (22) . Therefore, among patients without albuminuria for whom cardiovascular disease prevention is the primary goal of blood pressure control, a thiazide-like diuretic or dihydropyridine calcium channel blocker may be considered instead of or in addition to an ACE inhibitor or ARB.
There are no adequate head-to-head comparisons of ACE inhibitors and ARBs, but there is clinical trial support for each of the following statements: In patients with type 1 diabetes with hypertension and any degree of albuminuria, ACE inhibitors have been shown to reduce loss of glomerular filtration rate and delay the progression of nephropathy. In patients with type 2 diabetes, hypertension, and UACR 30-299 mg/g creatinine, ACE inhibitors and ARBs have been shown to delay the progression to UACR $300 mg/g creatinine. The use of both ACE inhibitors and ARBs in combination is not recommended given the lack of added ASCVD benefit and increased rate of adverse eventsdnamely, hyperkalemia, syncope, and acute kidney injury (34,35).
Combination Drug Therapy
The blood pressure arm of the ADVANCE trial demonstrated that routine administration of a fixed-dose combination of the ACE inhibitor perindopril and the thiazide-like diuretic indapamide significantly reduced combined microvascular and macrovascular outcomes, as well as death from cardiovascular causes and total mortality. The improved outcomes could also have been due to lower achieved blood pressure in the perindopril-indapamide arm (15) . Another trial showed a decrease in morbidity and mortality in those receiving ACE inhibitor benazepril and calcium channel blocker amlodipine versus benazepril and thiazide-like diuretic hydrochlorothiazide (36, 37) . If needed to achieve blood pressure targets, amlodipine and indapamide or hydrochlorothiazide or thiazide-like diuretic chlorthalidone can be added. If estimated glomerular filtration rate is ,30 mL/min/1.73 m 2 , a loop diuretic should be prescribed. Titration of and/or addition of further blood pressure medications should be made in a timely fashion to overcome clinical inertia in achieving blood pressure targets.
Bedtime Dosing
Growing evidence suggests that there is an association between absence of nocturnal blood pressure dipping and the incidence of ASCVD. A randomized controlled trial of 448 participants with type 2 diabetes and hypertension demonstrated reduced cardiovascular events and mortality with median follow-up of 5.4 years if at least one antihypertensive medication was given at bedtime (38) . Consider administering one or more antihypertensive medications at bedtime (39) .
Other Considerations
An important caveat is that most patients with diabetes and hypertension require multiple-drug therapy to reach blood pressure treatment goals (21) . Identifying and addressing barriers to medication adherence (such as cost and side effects) should routinely be done. If blood pressure remains uncontrolled despite confirmed adherence to optimal doses of at least three antihypertensive agents of different classes, one of which should be a diuretic, clinicians should consider an evaluation for secondary causes of hypertension.
Pregnancy and Antihypertensive Medications
Since there is a lack of randomized controlled trials of antihypertensive therapy in pregnant women with diabetes, recommendations for the management of hypertension in pregnant women with diabetes should be similar to those for all pregnant women. The American College of Obstetricians and Gynecologists (ACOG) has recommended that women with mild gestational hypertension (SBP ,160 mmHg or DBP ,110 mmHg) do not need to be treated with antihypertensive medications as there is no benefit identified that clearly outweighs potential risks of therapy (40) . A 2014 Cochrane systematic review of antihypertensive therapy for mild to moderate chronic hypertension that included 49 trials and over 4,700 women did not find any conclusive evidence for or against blood pressure treatment to reduce the risk of preeclampsia for the mother or effects on perinatal outcomes such as preterm birth, small-for-gestational-age infants, or fetal death (41) . For pregnant women who require antihypertensive therapy, SBP levels of 120-160 mmHg and DBP levels of 80-105 mmHg are suggested to optimize maternal health without risking fetal harm. Lower targets (SBP 110-119 mmHg and DBP 65-79 mmHg) may contribute to improved long-term maternal health; however, they may be associated with impaired fetal growth. Pregnant women with hypertension and evidence of end-organ damage from cardiovascular and/or renal disease may be considered for lower blood pressure targets to avoid progression of these conditions during pregnancy.
During pregnancy, treatment with ACE inhibitors, ARBs, and spironolactone are contraindicated as they may cause fetal damage. Antihypertensive drugs known to be effective and safe in pregnancy include methyldopa, labetalol, hydralazine, carvedilol, clonidine, and long-acting nifedipine (40) . Diuretics are not recommended for blood pressure control in pregnancy but may be used during late-stage pregnancy if needed for volume control (40, 42) . ACOG also recommends that postpartum patients with gestational hypertension, preeclampsia, and superimposed preeclampsia have their blood pressures observed for 72 h in hospital and for 7-10 days postpartum. Long-term follow-up is recommended for these women as they have increased lifetime cardiovascular risk (43) . (53) . As in those without diabetes, absolute reductions in ASCVD outcomes (CHD death and nonfatal MI) are greatest in people with high baseline ASCVD risk (known ASCVD and/or very high LDL cholesterol levels), but the overall benefits of statin therapy in people with diabetes at moderate or even low risk for ASCVD are convincing (54, 55) . Statins are the drugs of choice for LDL cholesterol lowering and cardioprotection.
LIPID MANAGEMENT
Most trials of statins and ASCVD outcomes tested specific doses of statins against placebo or other statins rather than aiming for specific LDL cholesterol goals (56) , suggesting that the initiation and intensification of statin therapy be based on risk profile ( 
Ongoing Therapy and Monitoring With Lipid Panel
In adults with diabetes, it is reasonable to obtain a lipid profile (total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides) at the time of diagnosis, at the initial medical evaluation, and at least every 5 years thereafter. A lipid panel should also be obtained immediately before initiating statin therapy. Once a patient is taking a statin, testing for LDL cholesterol may be considered on an individual basis (e.g., to monitor for adherence and efficacy). In cases where patients are adherent but the LDL cholesterol level is not responding, clinical judgment is recommended to determine the need for and timing of lipid panels. In individual patients, the highly variable LDL cholesterol-lowering response seen with statins is poorly understood (61) . When maximally tolerated doses of statins fail to substantially lower LDL cholesterol (,30% reduction from the patient's baseline), there is no strong evidence that combination therapy should be used. Clinicians should attempt to find a dose or alternative statin that is tolerable, if side effects occur. There is evidence for benefit from even extremely low, less than daily, statin doses (62) .
Increased frequency of LDL cholesterol monitoring should be considered for patients with new-onset ACS. Increased frequency of LDL cholesterol monitoring may also be considered in adults with heterozygous familial hypercholesterolemia who require additional lowering of LDL cholesterol. (63) . Therefore, for people meeting IMPROVE-IT eligibility criteria, ezetimibe should be added to moderate-intensity statin therapy.
Though not explicitly studied, these results may also suggest that the addition of ezetimibe should be considered for any patient with diabetes and history of ASCVD who cannot tolerate high-intensity statin therapy.
Statins and PCSK9 Inhibitors
Placebo-controlled trials evaluating the addition of the PCSK9 inhibitors evolocumab and alirocumab to maximally tolerated doses of statin therapy in participants who were at high risk for ASCVD demonstrated an average reduction in LDL cholesterol ranging from 36% to 59%. These agents may therefore be considered as adjunctive therapy for patients with diabetes at high risk for ASCVD events who require additional lowering of LDL cholesterol or who require but are intolerant to high-intensity statin therapy (64, 65) . It is important to note that the effects of this novel class of agents on ASCVD outcomes are unknown as phase 4 studies are currently under way.
Treatment of Other Lipoprotein Fractions or Targets
Hypertriglyceridemia should be addressed with dietary and lifestyle changes including abstinence from alcohol (66) . Severe hypertriglyceridemia (.1,000 mg/dL) may warrant pharmacologic therapy (fibric acid derivatives and/or fish oil) to reduce the risk of acute pancreatitis.
Low levels of HDL cholesterol, often associated with elevated triglyceride levels, are the most prevalent pattern of dyslipidemia in individuals with type 2 diabetes. However, the evidence for the use of drugs that target these lipid fractions is substantially less robust than that for statin therapy (67) . In a large trial in patients with diabetes, fenofibrate failed to reduce overall cardiovascular outcomes (68).
Combination Therapy
Statin and Fibrate
Combination therapy (statin and fibrate) is associated with an increased risk for abnormal transaminase levels, myositis, and rhabdomyolysis. The risk of rhabdomyolysis is more common with higher doses of statins and renal insufficiency and appears to be higher when statins are combined with gemfibrozil (compared with fenofibrate) (69) .
In the ACCORD study, in patients with type 2 diabetes who were at high risk for ASCVD, the combination of fenofibrate and simvastatin did not reduce the rate of fatal cardiovascular events, nonfatal MI, or nonfatal stroke as compared with simvastatin alone. Prespecified subgroup analyses suggested heterogeneity in treatment effects with possible benefit for men with both a triglyceride level $204 mg/dL (2.3 mmol/L) and an HDL cholesterol level #34 mg/dL (0.9 mmol/L) (70).
Statin and Niacin
The Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes (AIM-HIGH) trial randomized over 3,000 patients (about one-third with diabetes) with established ASCVD, low LDL cholesterol levels (,180 mg/dL [4.7 mmol/L]), low HDL cholesterol levels (men ,40 mg/dL [1.0 mmol/L] and women ,50 mg/dL [1.3 mmol/L]), and triglyceride levels of 150-400 mg/dL (1.7-4.5 mmol/L) to statin therapy plus extended-release niacin or placebo. The trial was halted early due to lack of efficacy on the primary ASCVD outcome (first event of the composite of death from CHD, nonfatal MI, ischemic stroke, hospitalization for an ACS, or symptom-driven coronary or cerebral revascularization) and a possible increase in ischemic stroke in those on combination therapy (71). Therefore, combination therapy with a statin and niacin is not recommended given the lack of efficacy on major ASCVD outcomes, possible increase in risk of ischemic stroke, and side effects.
Diabetes With Statin Use
Several studies have reported an increased risk of incident diabetes with statin use (72, 73) , which may be limited to those with diabetes risk factors. An analysis of one of the initial studies suggested that although statins were linked to diabetes risk, the cardiovascular event rate reduction with statins far outweighed the risk of incident diabetes even for patients at highest risk for diabetes (74) . The absolute risk increase was small (over 5 years of follow-up, 1.2% of participants on placebo developed diabetes and 1.5% on rosuvastatin developed diabetes) (74) . A meta-analysis of 13 randomized statin trials with 91,140 participants showed an odds ratio of 1.09 for a new diagnosis of diabetes, so that (on average) treatment of 255 patients with statins for 4 years resulted in one additional case of diabetes while simultaneously preventing 5.4 vascular events among those 255 patients (73).
Statins and Cognitive Function
A recent systematic review of the U.S. Food and Drug Administration's postmarketing surveillance databases, randomized controlled trials, and cohort, case-control, and cross-sectional studies evaluating cognition in patients receiving statins found that published data do not reveal an adverse effect of statins on cognition. Therefore, a concern that statins might cause cognitive dysfunction or dementia should not deter their use in individuals with diabetes at high risk for ASCVD (75) . Aspirin has been shown to be effective in reducing cardiovascular morbidity and mortality in high-risk patients with previous MI or stroke (secondary prevention). Its net benefit in primary prevention among patients with no previous cardiovascular events is more controversial both for patients with diabetes and for patients without diabetes (76, 77) . Previous randomized controlled trials of aspirin specifically in patients with diabetes failed to consistently show a significant reduction in overall ASCVD end points, raising questions about the efficacy of aspirin for primary prevention in people with diabetes, although some sex differences were suggested (78-80). The Antithrombotic Trialists' (ATT) collaborators published an individual patient-level meta-analysis of the six large trials of aspirin for primary prevention in the general population. These trials collectively enrolled over 95,000 participants, including almost 4,000 with diabetes. Overall, they found that aspirin reduced the risk of serious vascular events by 12% (RR 0.88 [95% CI 0.82-0.94]). The largest reduction was for nonfatal MI, with little effect on CHD death (RR 0.95 [95% CI 0.78-1.15]) or total stroke. There was some evidence of a difference in aspirin effect by sex: aspirin significantly reduced ASCVD events in men but not in women. Conversely, aspirin had no effect on stroke in men but significantly reduced stroke in women. However, there was no heterogeneity of effect by sex in the risk of serious vascular events (P 5 0.9).
ANTIPLATELET AGENTS
Sex differences in aspirin's effects have not been observed in studies of secondary prevention (76) . In the six trials examined by the ATT collaborators, the effects of aspirin on major vascular events were similar for patients with or without diabetes: RR 0.88 (95% CI 0.67-1.15) and RR 0.87 (95% CI 0.79-0.96), respectively. The confidence interval was wider for those with diabetes because of smaller numbers.
Aspirin appears to have a modest effect on ischemic vascular events, with the absolute decrease in events depending on the underlying ASCVD risk. The main adverse effects appear to be an increased risk of gastrointestinal bleeding. The excess risk may be as high as 1-5 per 1,000 per year in real-world settings. In adults with ASCVD risk .1% per year, the number of ASCVD events prevented will be similar to or greater than the number of episodes of bleeding induced, although these complications do not have equal effects on long-term health (81) .
Treatment Considerations
In 2010, a position statement of the ADA, the American Heart Association, and the American College of Cardiology Foundation recommended that low-dose (75-162 mg/day) aspirin for primary prevention is reasonable for adults with diabetes and no previous history of vascular disease who are at increased ASCVD risk and who are not at increased risk for bleeding (82) . This previous statement included sex-specific recommendations for use of aspirin therapy as primary prevention persons with diabetes. However, since that time, multiple recent well-conducted studies and meta-analyses have reported a risk of heart disease and stroke that is equivalent if not higher in women compared with men with diabetes, including among nonelderly adults. Thus, current recommendations for using aspirin as primary prevention include both men and women aged $50 years with diabetes and at least one additional major risk factor (family history of premature ASCVD, hypertension, dyslipidemia, smoking, or chronic kidney disease/ albuminuria) who are not at increased risk of bleeding (83) (84) (85) (86) . While risk calculators such as those from the American College of Cardiology/American Heart Association (http://my.americanheart.org) may be a useful tool to estimate 10-year ASCVD risk, diabetes itself confers increased risk for ASCVD. As a result, such risk calculators have limited utility in helping to assess the potential benefits of aspirin therapy in individuals with diabetes. Noninvasive imaging techniques such as coronary computed tomography angiography may potentially help further tailor aspirin therapy, particularly in those at low risk (87), but are not generally recommended. Sex differences in the antiplatelet effect of aspirin have been suggested in the general population (88); however, further studies are needed to investigate the presence of such differences in individuals with diabetes.
Aspirin Use in People <50 Years of Age
Aspirin is not recommended for those at low risk of ASCVD (such as men and women aged ,50 years with diabetes with no other major ASCVD risk factors) as the low benefit is likely to be outweighed by the risks of bleeding. Clinical judgment should be used for those at intermediate risk (younger patients with one or more risk factors or older patients with no risk factors) until further research is available. Patients' willingness to undergo long-term aspirin therapy should also be considered (89) . Aspirin use in patients aged ,21 years is generally contraindicated due to the associated risk of Reye syndrome.
Aspirin Dosing
Average daily dosages used in most clinical trials involving patients with diabetes ranged from 50 mg to 650 mg but were mostly in the range of 100-325 mg/day. There is little evidence to support any specific dose, but using the lowest possible dose may help to reduce side effects (90) . In the U.S., the most common low-dose tablet is 81 mg. Although platelets from patients with diabetes have altered function, it is unclear what, if any, effect that finding has on the required dose of aspirin for cardioprotective effects in the patient with diabetes. Many alternate pathways for platelet activation exist that are independent of thromboxane A 2 and thus not sensitive to the effects of aspirin (91) . "Aspirin resistance" has been described in patients with diabetes when measured by a variety of ex vivo and in vitro methods (platelet aggregometry, measurement of thromboxane B 2 ) (88), but other studies suggest no impairment in aspirin response among patients with diabetes (92) . A recent trial suggested that more frequent dosing regimens of aspirin may reduce platelet reactivity in individuals with diabetes (93); however, these observations alone are insufficient to empirically recommend that higher doses of aspirin be used in this group at this time. It appears that 75-162 mg/day is optimal.
Indications for P2Y12 Use
A P2Y12 receptor antagonist in combination with aspirin should be used for at least 1 year in patients following an ACS and may have benefits beyond this period. Evidence supports use of either ticagrelor or clopidogrel if no percutaneous coronary intervention was performed and clopidogrel, ticagrelor, or prasugrel if a percutaneous coronary intervention was performed (94) . In patients with diabetes and prior MI (1-3 years before), adding ticagrelor to aspirin significantly reduces the risk of recurrent ischemic events including cardiovascular and coronary heart disease death (95) . More studies are needed to investigate the longer-term benefits of these therapies after ACS among patients with diabetes. (100, 106, 107) , the role of these tests beyond risk stratification is not clear. Their routine use leads to radiation exposure and may result in unnecessary invasive testing such as coronary angiography and revascularization procedures. The ultimate balance of benefit, cost, and risks of such an approach in asymptomatic patients remains controversial, particularly in the modern setting of aggressive ASCVD risk factor control.
CORONARY HEART DISEASE
Lifestyle and Pharmacologic Interventions
Intensive lifestyle intervention focusing on weight loss through decreased caloric intake and increased physical activity as performed in the Action for Health in Diabetes (Look AHEAD) trial may be considered for improving glucose control, fitness, and some ASCVD risk factors (108). Patients at increased ASCVD risk should receive aspirin and a statin and ACE inhibitor or ARB therapy if the patient has hypertension, unless there are contraindications to a particular drug class. While clear benefit exists for ACE inhibitor and ARB therapy in patients with nephropathy or hypertension, the benefits in patients with ASCVD in the absence of these conditions are less clear, especially when LDL cholesterol is concomitantly controlled (109, 110) . In patients with prior MI, b-blockers should be continued for at least 2 years after the event (111).
Diabetes and Heart Failure
As many as 50% of patients with type 2 diabetes may develop heart failure (112) . Data on the effects of glucose-lowering agents on heart failure outcomes have demonstrated that thiazolidinediones have a strong and consistent relationship with heart failure (113-115). Therefore, thiazolidinedione use should be avoided in patients with symptomatic heart failure. Recent studies have also examined the relationship between dipeptidyl peptidase 4 (DPP-4) inhibitors and heart failure and have had mixed results. The Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus-Thrombolysis in Myocardial Infarction 53 (SAVOR-TIMI 53) study showed that patients treated with saxagliptin (a DPP-4 inhibitor) were more likely to be hospitalized for heart failure than were those given placebo (3.5% vs. 2.8%, respectively) (116) . Two other recent multicenter, randomized, double-blind, noninferiority trials, Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care (EXAMINE) and Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS), did not show associations between DPP-4 inhibitor use and heart failure. EXAMINE reported that the hospital admission rate for heart failure was 3.1% for patients randomly assigned to alogliptin compared with 2.9% for those randomly assigned to placebo (hazard ratio 1.07 [95% CI 0.79-1.46]) (117) . Alogliptin had no effect on the composite end point of cardiovascular death and hospital admission for heart failure in the post hoc analysis (hazard ratio 1.00 [95% CI 0.82-1.21]) (117) . TECOS showed a nonsignificant difference in the rate of heart failure hospitalization for the sitagliptin group (3.1%; 1.07 per 100 person-years) compared with the placebo group (3.1%; 1.09 per 100 person-years) (118) .
Antihyperglycemic Therapies and Cardiovascular Outcomes
Recently published cardiovascular outcome trials have provided additional data on cardiovascular outcomes in patients with type 2 diabetes with cardiovascular disease or at high risk for cardiovascular disease. The BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME) was a randomized, double-blind trial that assessed the effect of empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, versus placebo and standard care on cardiovascular outcomes in patients with type 2 diabetes and existing cardiovascular disease. Study participants had a mean age of 63 years, 57% had diabetes for more than 10 years, and 99% had established cardiovascular disease. EMPA-REG OUTCOME showed that over a median follow-up of 3.1 years, treatment reduced the composite outcome of MI, stroke, and cardiovascular death by 14% (absolute rate 10.5% vs. 12.1% in the placebo group) and cardiovascular death by 38% (absolute rate 3.7% vs. 5.9%) (119) . The FDA recently added a new indication for empagliflozin, to reduce the risk of cardiovascular death in adults with type 2 diabetes and cardiovascular disease. Whether other SGLT2 inhibitors will have the same effect in high-risk patients and whether empagliflozin or other SGLT2 inhibitors will have a similar effect in lower-risk patients with diabetes remains unknown.
The Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome ResultsdA Long Term Evaluation (LEADER) trial was a randomized, doubleblind trial that assessed the effect of liraglutide, a glucagon-like peptide 1 receptor agonist, versus placebo and standard care on cardiovascular outcomes in patients with type 2 diabetes at high risk for cardiovascular disease or with cardiovascular disease. Study participants had a mean age of 64 years and a mean duration of diabetes of nearly 13 years. Over 80% of study participants had established cardiovascular disease inclusive of a prior MI, prior stroke or transient ischemic attack, prior revascularization procedure, or $50% stenosis of coronary, carotid, or lower-extremity arteries. LEADER showed that the composite primary outcome (MI, stroke, or cardiovascular death) occurred in fewer participants in the treatment group (13.0%) when compared with the placebo group (14.9%) after a median follow-up of 3.8 years (120) . Whether other glucagon-like peptide 1 receptor agonists will have the same effect in high-risk patients or if this drug class will have similar effects in lower-risk patients with diabetes remains unknown.
